GlobalData on MSN
ImmunityBio’s Anktiva shows success as combo treatment in NSCLC
Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
TROPION-Lung17 will enroll approximately 400 patients across global sites. Participants are randomized 1:1 to receive either ...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Timing of consolidation durvalumab significantly impacts survival for patients with locally advanced non-small cell lung ...
Explore the latest HER2-targeted therapies for non-small cell lung cancer, including treatment options and patient-centered decision-making strategies.
Stocktwits on MSN
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients
The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...
Market Dynamix™ is an independent, data-driven service focused on understanding the evolving dynamics of specialty markets poised for disruption. Leveraging quantitative and qualitative research, the ...
The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. | The emergence of ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
BioNTech's gotistobart receives FDA orphan drug designation, showing promise in improving survival for patients with squamous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback